eye Insights Issue 02: Fueling a Revolution in Retinal Care

Eye Insights 2 CoverHow biomedical breakthroughs in anti-VEGF research have changed how we diagnose, treat, and save vision for patients with retinal disease.

  • Annually, 500,000 ophthalmic patients in the United States and over 1 million worldwide are treated with all anti-VEGF agents combined.
  • Anti-VEGF treatments have been shown to halt vision loss in more than 90 percent of patients with AMD and to improve vision in one-third.
  • VEGF inhibitors hold potential for a growing list of indications, including neovascular glaucoma and retinopathy of prematurity.
  • VEGF inhibitors have been used experimentally to treat over 50 ocular diseases.


Editor-in-Chief: Joan W. Miller, MD, FARVO
Managing Editor: Matthew F. Gardiner, MD
Communications Director: Suzanne Ward
Scientific Communications Manager: Wendy Chao, PhD
Clinical Advisory Group: Carolyn E. Kloek, MD, Deeba Husain, MD, Ankoor S. Shah, MD, PhD, Angela V. Turalba, MD

Browse all issues >>    |    Email: eyeinsights@meei.harvard.edu


eye Insights 2 PDF2.37 MB
See also: eye Insights